By Joe Dustin
For nearly 20 years, the industry has been made aware of the benefits of electronic clinical outcome assessments (eCOA). In 2009, the FDA published its final ePRO guidance, signaling that the industry was ready for mass adoption of the technology. However, by 2015, it was reported by Industry Standard Research that nearly half of clinical researchers were still using traditional paper methods.11
Since then, additional reports have indicated that the life sciences industry is at the precipice of a digital tipping point. Clinical development teams are now including more opportunities to directly capture the patient's voice and reflect them within study protocols because of the increased pervasiveness of technology, solutions that scale across more therapeutic areas, and clinical trial design.
Analysts suggest that eCOA is poised to grow even more, with Data Bridge Market Research predicting that the eCOA market will grow by 3 billion2 over the next five years. Discover how eCOA technology is revolutionizing data collection, improving patient experiences, and enhancing trial outcomes.